Recently, a decoy peptide Bcl-2-IP3R disrupter-2 (BIRD-2) targeted to the BH4 domain of Bcl-2 has been developed for cancer treatment. In vitro and in vivo studies have demonstrated that BIRD-2 propels IP3R-mediated Ca2+ signaling and causes pronounced apoptosis in Bcl-2 positive cancer models, including MM, follicular lymphoma and chronic lymphocytic leukemia [235]. The gene discussed is BCL2; the disease is Miyoshi myopathy.